Skip to main content
SpringerLink
Log in

Systematic Approach to Radiology of Endocrine Disorders Affecting the Musculoskeletal System

  • Chapter
  • First Online:
Diagnostic Imaging of Musculoskeletal Diseases

  • 2275 Accesses

Abstract

Diagnostic imaging has two major roles in the management of the patients with endocrine dysfunction:

  1. (1)

    Localization of the abnormal endocrine gland and demonstration of the nature and extent of abnormality.

  2. (2)

    Visualizing the radiological musculoskeletal abnormalities in target organs.

Localization of the abnormal endocrine gland and demonstration of the nature and extent of abnormality.

Visualizing the radiological musculoskeletal abnormalities in target organs.

Gigantism and acromegaly are caused by excessive secretion of growth hormone. MRI is the best imaging modality for localization of the pituitary adenoma. Endocrine causes of attenuated growth include hormonal deficiencies such as GH deficiency and congenital hypothyroidism. In congenital hypothyroidism the body appears immature for the chronological age. Untreated overt hyperthyroidism is clearly associated with osteoporosis and an increased risk of fracture. The pathognomonic finding in well-established primary or secondary hyperparathyroidism is subperiosteal resorption. Renal osteodystrophy is the most common cause of secondary hyperparathyroidism in the western world. Amyloidosis and destructive spondyloarthropathy are major complications of dialysis. Ischemic necrosis of bone is a major complication of renal transplantation.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 279.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Chen EY, Liao YC, Smith DH, et al. The growth hormone locus: nucleotide sequence, biology, and evolutions. Genomics 1989; 4:479.

    Article  CAS  PubMed  Google Scholar 

  2. Hartman ML, Veldhuis JD, Thorner MO. Normal control of growth hormone secretion. Hormones 1993; 40(1–3):37–47.

    Google Scholar 

  3. Faustini-Fustini M, Rochira V, Carani C. Eur J Endocrinol 1999; 140:111–129.

    Article  CAS  PubMed  Google Scholar 

  4. Smith EP, Boyd J, Frank GR, et al. N Engl J Med 1994; 331:1056–1061.

    Article  CAS  PubMed  Google Scholar 

  5. Gelber SJ, Heffez DS, Donohoue PA. Pituitary gigantism caused by growth hormone excess from infancy. J Pediatric 1992; 120(6):931–934.

    Article  CAS  Google Scholar 

  6. Blumberg DL, Sklar CA, David R, et al. Acromegaly in an infant. Pediatrics 1989; 83(6):998–1002.

    CAS  PubMed  Google Scholar 

  7. Zimmerman D, Young WF, Ebersold MJ, et al. Congenital gigantism due to growth hormone releasing hormone excess and pituitary hyperplasia with adenomatous transformation. J Clin Endocrinol Metab 1993; 76(1):216–222.

    Article  CAS  PubMed  Google Scholar 

  8. Manski TJ, Haworth CS, Duval-Arnold BJ, et al. Optic pathway glioma infiltrating into somatostatinergic pathways in a young boy with gigantism. Case report. J Neurosurg 1994; 81(4):595–600.

    Article  CAS  PubMed  Google Scholar 

  9. Thorner MO, Perryman RL, Cronin MJ, et al. Somatotroph hyperplasia: successful treatment of acromegaly by removal of a pancreatic tumor secreting a growth hormone releasing factor. J Clin Invest 1982; 70:965.

    Article  CAS  PubMed  Google Scholar 

  10. Ludecke DK, Herrmann HD, Schulte FJ. Special problems with neurosurgical treatments of hormone-secreting pituitary adenomas in children. Prog Exp Tumor Res 1987; 30:362.

    CAS  PubMed  Google Scholar 

  11. Ritzen EM, Wettrell G, Davies G, Grant DB. Management of pituitary gigantism. The role of bromocriptine and radiotherapy. Acta Paediatr Scand 1985 Sep; 74(5):807–814.

    Article  CAS  PubMed  Google Scholar 

  12. Zacharin M. Paediatric management of endocrine complications in McCune-Albright syndrome. J Pediatr Endocrinol Metab. 2005 Jan; 18(1):33–41.

    PubMed  Google Scholar 

  13. Moran A, Pescovitz OH. Long-term treatment of gigantism with combination octreotide and bromocriptine in a child with McCune-Albright syndrome. Endocr J 1994; 2:111.

    Google Scholar 

  14. Sotos JF, Dodge PR, Muirhead D, et al. Cerebral gigantism in childhood. N Engl J Med 1964; 271:109–116.

    Article  CAS  PubMed  Google Scholar 

  15. Tatton-Brown K, Douglas J, Coleman K, et al. Genotype–phenotype associations in Sotos syndrome: an analysis of 266 individuals with NSD1 aberrations. Am J Hum Genet 2005; 77:193–204.

    Article  CAS  PubMed  Google Scholar 

  16. Kurotaki N, Imaizumi K, Harada N, et al. Haploinsufficiency of NSD1 causes Sotos syndrome. Nat Genet 2002; 30:365–366.

    Article  CAS  PubMed  Google Scholar 

  17. Wit JM, Beemer FA, Barth PG, et al. Cerebral gigantism (Sotos’ syndrome). Compiled data 22 cases. Analysis of clinical features, growth and plasma somatomedin. Eur J Pediatr 1985; 144:131.

    Article  CAS  PubMed  Google Scholar 

  18. Scheithauer BW, Kovacs K, Randall RV, Horvath E, Laws ER Jr. Pathology of excessive production of growth hormone. Clin Endocrin & Metab 1986; 15:655.

    Article  CAS  Google Scholar 

  19. Karpf DB, Braunstein GD. Current concepts in acromegaly: etiology, diagnosis and treatment. Compr Ther 1986; 12:22.

    CAS  PubMed  Google Scholar 

  20. Holdaway IM, Rajasoorya C. Epidemiology of acromegaly. Pituitary 1999; 2:29–41.

    Article  CAS  PubMed  Google Scholar 

  21. Sanno N, Teramoto A, Osamura RY, et al. Pathology of pituitary tumors. Neurosurg Clin N Am 2003; 14:25–39.

    Article  PubMed  Google Scholar 

  22. Melmed S. Acromegaly. N Engl J Med 1990; 322:966–977.

    Article  CAS  PubMed  Google Scholar 

  23. Melmed S, Ezrin C, Kovacs K, et al. Acromegaly due to secretion of growth hormone by an ectopic pancreatic islet-cell tumor. N Engl J Med 1985; 312:9.

    Article  CAS  PubMed  Google Scholar 

  24. Beuschlein F, Strasburger CJ, Siegerstetter V, et al. Acromegaly caused by secretion of growth hormone by a non-Hodgkin’s lymphoma. N Engl J Med 2000; 342:1871.

    Article  CAS  PubMed  Google Scholar 

  25. Biermasz NR, Pereira AM, Smit JW, et al. Morbidity after long-term remission for acromegaly: persisting joint-related complaints cause reduced quality of life. J Clin Endocrinol Metab 2005; 90:2731.

    Article  CAS  PubMed  Google Scholar 

  26. Melmed S, Jackson I, Kleinberg D, et al. Current treatment guidelines for acromegaly. J Clin Endocrin Metab 1998; 83(8):2646–2652.

    Article  CAS  Google Scholar 

  27. Trainer PJ, Drake WM, Katznelson L, et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med 2000; 342:1171–1177.

    Article  CAS  PubMed  Google Scholar 

  28. van der Lely AJ, Hutson RK, Trainor PJ et al., Long-term treatment of acromegaly with pegvisomant, a growth hormone-receptor antagonist. Lancet 2001; 358:1754–1759.

    Article  PubMed  Google Scholar 

  29. Kauppinen-Makelin R, Sane T, Reunanen A, Valimaki MJ, Niskanen L, Markkanen H, Loyttyniemi E, Ebeling T, Jaatinen P, Laine H, Nuutila P, Salmela P, Salmi J, Stenman UH, Viikari J, Voutilainen E. A nationwide survey of mortality in acromegaly. J Clin Endocrinol & Metabol 2005 Jul; 90(7):4081–4086.

    Article  Google Scholar 

  30. Rosenfeld RG, Albertsson-Wikland K, Cassorla F, et al. Diagnostic controversy: the diagnosis of childhood growth hormone deficiency revisited. J Clin Endocrinol Metab 1995; 80:1532.

    Article  CAS  PubMed  Google Scholar 

  31. Root AW, Kemp SF, Rundle AC, et al. Effect of long-term recombinant growth hormone therapy in children – the National Cooperative Growth Study, USA, 1985–1994. J Pediatr Endocrinol Metab 1998; 11:403.

    CAS  PubMed  Google Scholar 

  32. Chernausek SD, Backeljauw PF, Frane J, et al. Long-term treatment with recombinant insulin-like growth factor (IGF)-I in children with severe IGF-I deficiency due to growth hormone insensitivity. J Clin Endocrinol Metab 2007; 92:902.

    Article  CAS  PubMed  Google Scholar 

  33. Allen DB. Growth suppression by glucocorticoid therapy. Endocrinol Metab Clin North Am 1996; 25:699.

    Article  CAS  PubMed  Google Scholar 

  34. Delange F. Neonatal screening for congenital hypothyroidism: results and perspectives. Horm Res 1997; 48:51–61.

    Article  CAS  PubMed  Google Scholar 

  35. Alm J, Hagenfeldt LA, et al. Incidence of congenital hypothyroidism: retrospective study of neonatal laboratory screening versus clinical symptoms as indicators leading to diagnosis. BMJ 1984; 289:1171.

    Article  CAS  PubMed  Google Scholar 

  36. Harris F. In R Owen, J Goodfellow, P Bullough (Eds.), Hormonal Control of Growth in Scientific Foundations of Orthopedics and Traumatology. Rickets and Osteomalacia. Philadelphia: W.B. Saunders, 1980.

    Google Scholar 

  37. Poretsky L, Garber J, Kleefield J. Primary amenorrhea and pseudoprolactinama with primary hypothyroidism. Reversal of clinical, biochemical, and radiologic abnormalities with levothyroxine. Am J Med 1986; 81:180.

    Article  CAS  PubMed  Google Scholar 

  38. Katevuo K, Valimaki M, Ketonen L, Lamberg B-A, Pelkonen R. Computed tomography of the pituitary fossa in primary hypothyroidism. Effect of thyroxine treatment. Clin Endocrinol 1985; 2:617.

    Article  Google Scholar 

  39. Ross DS. Hyperthyroidism, thyroid hormone therapy and bone. Thyroid 1994; 4:39.

    Article  Google Scholar 

  40. Mosekilde L, Eriksen EF, Charles P. Effects of thyroid hormones on bone and mineral metabolism. Endocrinol Metab Clin North Am 1990; 19:35.

    CAS  PubMed  Google Scholar 

  41. Jastrup B, Mosekilde L, Melsen F, et al. Serum levels of vitamin D metabolites and bone remodeling in hyperthyroidism. Metabolism 1982; 31:126.

    Article  CAS  PubMed  Google Scholar 

  42. Mudde AH, Houben JHM, Kruseman ACN. Bone metabolism during anti-thyroid drug treatment of endogenous subclinical hyperthyroidism. Clin Endocrinol 1994; 41:421.

    Article  CAS  Google Scholar 

  43. Cummings SR, Nevitt MC, Browner WS, et al. Risk factors for hip fracture in white women. N Engl J Med 1995; 332:767.

    Article  CAS  PubMed  Google Scholar 

  44. Bonakdarpour A, Kirkpatrick JA, Renzi A, Kendall N. Skeletal changes in neonatal thyro-toxicosis. Radiol 1971; 102:149–150.

    Google Scholar 

  45. Akerstrom G, Malmaeus J, Bergstrom R. Surgical anatomy of human parathyroid glands. Surgery 1984; 95:14.

    CAS  PubMed  Google Scholar 

  46. Ruda JM, Hollenbeak CS, Stack BC Jr. A systematic review of the diagnosis and treatment of primary hyperparathyroidism from 1995 to 2003. Otolaryngol Head Neck Surg 2005; 132:359.

    Article  PubMed  Google Scholar 

  47. Silverberg SJ, Bilezikian JP. Clinical presentation of primary hyperparthyroidism in the United States. In JP Bilezikian, et al. (Eds.), The Parathyroids, 2nd ed. New York: Academic Press, 2001; 349–360.

    Chapter  Google Scholar 

  48. Silverberg SJ, Bilezikian JP. Evaluation and management of primary hyperparathyroidism. J Clin Endocrinol Metab 1996; 81:2036.

    Article  CAS  PubMed  Google Scholar 

  49. Bilezikian JP, Brandi ML, Rubin M, Silverberg SJ. Primary hyperparathyroidism: new concepts in clinical, densitometric and biochemical features. J Intern Med 2005; 257:6.

    Article  CAS  PubMed  Google Scholar 

  50. Silverberg SJ, Bilezikian JP. Nat Clin Pract Endocrinol Metab 2006; 2:494–503.

    Article  PubMed  Google Scholar 

  51. Clark OH. How should patients with primary hyperparathyroidism be treated? J Clin Endocrinol Metab 2003; 88:3011–3014.

    Article  PubMed  Google Scholar 

  52. Udelsman R, Donovan POI, Sokoll LT. One hundred consecutive minimally invasive parathyroid explorations. Ann Surg 2000; 232:331–339.

    Article  CAS  PubMed  Google Scholar 

  53. Chen H, Zeiger MA, Gordon TA, et al. Parathyroidectomy in Maryland: effects of an endocrine center. Surgery 1996; 120:948–952.

    Article  CAS  PubMed  Google Scholar 

  54. Chen H, Parkerson S, Udelsman R. Parathyroidectomy in the elderly: do the benefits outweigh the risks? World J Surg 1998; 22:531–535.

    Article  CAS  PubMed  Google Scholar 

  55. Bergenfelz A, Lindblom P, Tibblin S, Westerdahl J. Unilateral versus bilateral neck exploration for primary hyperparathyroidism: a prospective randomized controlled trial. Ann Surg 2002; 236:543–551.

    Article  PubMed  Google Scholar 

  56. Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. JAMA 2007; 298(17):2038–2047.

    Article  CAS  PubMed  Google Scholar 

  57. Holick MF. Vitamin D deficiency. N Engl J Med 2007; 357:266–281.

    Article  CAS  PubMed  Google Scholar 

  58. Silver J, Russell J, Sherwood LM. Regulation by vitamin D metabolites of messenger ribonucleic acid for preproparathyroid hormone in isolated bovine parathyroid cells. Proc Natl Acad Sci USA 1985; 82:4270–4273.

    Article  CAS  PubMed  Google Scholar 

  59. Dawson-Hughes B, Heaney RP, Holick MF, et al. Estimates of optimal vitamin D status. Osteoporos Int 2005; 16:713.

    Article  CAS  PubMed  Google Scholar 

  60. Vieth R. What is the optimal vitamin D status for health. Prog Biophys Mol Biol 2006; 92:26.

    Article  CAS  PubMed  Google Scholar 

  61. Marx SJ. Hyperparathyroid and hypoparathyroid disorders. N Engl J Med 2000; 343:1863–1875.

    Article  CAS  PubMed  Google Scholar 

  62. Ahmad R, Hammond JM. Primary, secondary, and tertiary hyperparathyroidism. Otolaryngol Clin North Am 2004 Aug; 37(4):701–713, vii–viii.

    Article  PubMed  Google Scholar 

  63. Stewart AF. Hypercalcemia associated with cancer. N Engl J Med 2005; 352:373–379.

    Article  CAS  PubMed  Google Scholar 

  64. Eftekhari F, Yousefzadeh DK. Primary infantile hyperparathyroidism: clinical, laboratory, and radiographic features in 21 cases. Skeletal Radiol 1982; 8(3):201–208.

    Article  CAS  PubMed  Google Scholar 

  65. Orwoll E, Silbert J, McClung M. Hypercalcemia asymptomatic neonatal familial. Pediatrics 1982; 69(1):109–111.

    CAS  PubMed  Google Scholar 

  66. K/DO0I. Clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42(Suppl 3):PS1–201.

    Article  Google Scholar 

  67. Bonakdarpour A. Renal osteodystrophy. Radiology Today, 4-A, Multinational Series, 1987; 119–124.

    Google Scholar 

  68. Bonakdarpour A. Renal osteodystrophy. RSNA Syllabus on Metabolic and endocrine disorders affecting the skeleton. 1981; Course 409B:1–12.

    Google Scholar 

  69. Murphy MD, Sartoris DJ, Quale JL, Pathria MN, Martin NL. Musculoskeletal manifestations of chronic renal insufficiency. Radiographics 1993; 13(2):357–379.

    Google Scholar 

  70. Stevens K. Musculoskeletal manifestations of chronic renal disease, 34th International Skeletal Society Refresher course 11B 2007; 1-6 Budapest.

    Google Scholar 

  71. Jevtic V. Imaging of renal osteodystrophy. Eur J Radiol 2003; 46(2):85–89.

    Article  CAS  PubMed  Google Scholar 

  72. Sperschneider H, Stein G. Bone disease after renal transplantation. Nephrol Dial Transplant 2003; 18:874–877.

    Article  PubMed  Google Scholar 

  73. Heaf J, Tvedegaard E, Kanstrup IL, Fogh-Andersen N. Hyperparathyroidism and long-term bone loss after renal transplantation. Clin Transplant 2003; 17(3):268–274.

    Article  PubMed  Google Scholar 

  74. Julian BA, Quarles LD, Niemann KM. Musculoskeletal complications after renal transplantation: pathogenesis and treatment. Am J Kidney Dis 1992; 19(2):99–120.

    CAS  PubMed  Google Scholar 

  75. Arnold A, Brown MF, Urena P, Gaz RD, et al. Monoclonality of parathyroid tumors in chronic renal failure and in primary parathyroid hyperplasia. J Clin Invest 1995; 95(5):2047–2053.

    Article  CAS  PubMed  Google Scholar 

  76. Drueke TB. The pathogenesis of parathyroid gland hyperplasia in chronic renal failure. Kidney Int 1995; 48(1):259–272.

    Article  CAS  PubMed  Google Scholar 

  77. Pearce SH, Williams C, Kifor O, et al. A familial syndrome of hypocalcemia with hypercalciuria due to mutations in the calcium-sensing receptor. New Engl J Med 1996; 335:1115–1122.

    Article  CAS  PubMed  Google Scholar 

  78. Pollak MR, Brown EM, Estep HL, et al. Autosomal dominant hypocalcaemia caused by a Ca2+-sensing receptor gene mutation. Nat Genet 1994; 8:303.

    Article  CAS  PubMed  Google Scholar 

  79. Albright F, Burnett CH, Smith PH, Parson W. Pseudohypoparathyroidism: an example of “Seabright-Bantam syndrome.” Report of three cases. Endocrinol 1942; 30:922.

    CAS  Google Scholar 

  80. Bastepe M, Juppner H. GNAS locus and pseudohypoparathyroidism. Horm Res 2005; 63:65.

    Article  CAS  PubMed  Google Scholar 

  81. Spiegel AM, Weinstein LS, Shenker A. Abnormalities in G protein-coupled signal transduction pathways in human disease. J Clin Invest 1993; 92:1119.

    Article  CAS  PubMed  Google Scholar 

  82. Murray T, Gomez I, Rao E, et al. Pseudohypoparathyroidism with osteitis fibrosa cystica: Direct demonstration of skeletal responsiveness to parathyroid hormone in cells cultured from bone. J Bone Miner Res 1993; 8:83–91.

    Article  CAS  PubMed  Google Scholar 

  83. Ish-Shalom S, Rao LG, Levine MA et al., Normal parathyroid hormone responsiveness of bone derived cells from a patient with pseudohypoparthyroidism. J Bone Miner Res 1996; 11:8–14.

    Article  CAS  PubMed  Google Scholar 

  84. Breslau NA, Weinstock RS. Regulation of 1,25 (OH) 2D synthesis in hypoparathyroidism and pseudohypoparathyroidism. Am J Physiol 1988; 255:E730–736.

    CAS  PubMed  Google Scholar 

  85. Drezner MK, Neelon FA, Haussler M, et al. 1,25-dihydroxycholecalicferol deficiency: the probable cause of hypocalcemia and metabolic bone disease in pseudohypoparathyroidism. J Clin Endocrinol Metab 1976; 42:621–628.

    Article  CAS  PubMed  Google Scholar 

  86. Chase LR, Melson GL, Aurbach GD. Pseudohypoparathyroidism: defective excretion of 3’5’-AMP in response to parathyroid hormone. J Clin Invest 1969; 48:1832–1844.

    Article  CAS  PubMed  Google Scholar 

  87. Drezner M, Neelon FA, Lebovitz HE. Pseudohypoparathyroidism type II: a possible defect in the reception of the cyclic AMP signal. N Engl J Med 1973; 289:1056.

    Article  CAS  PubMed  Google Scholar 

  88. Nakamoto JM, Sandstrom AT, Brickman AS, et al. Pseudohypoparathyroidism type Ia from maternal but not paternal transmission of a Gs alpha gene mutation. Am J Med Genet 1998; 77:261.

    Article  CAS  PubMed  Google Scholar 

  89. Levine MA, Downs RW Jr, Moses AM, et al. Resistance to multiple hormones in patients with pseudohypoparathyroidism. Association with deficient activity of guanine nucleotide regulatory protein. Am J Med 1983; 74:545.

    Article  CAS  PubMed  Google Scholar 

  90. Bastepe M, Jüppner H. GNAS locus and pseudohypoparathyroidism. Horm Res 2005; 63(2):65–74.

    Article  CAS  PubMed  Google Scholar 

  91. Hayward BE, Kamiya M, Strain L, et al. The human GNAS1 gene is imprinted and encodes distinct paternally and biallelically expressed G proteins. Proc Natl Acad Sci USA 1998; 95:10038.

    Article  CAS  PubMed  Google Scholar 

  92. Kaplan FS, Shore EM. Progressive osseous heteroplasia. J Bone Miner Res 2000; 15:2084–2094.

    Article  CAS  PubMed  Google Scholar 

  93. Shore EM, Ahn J, Jan de Beur S et al., Paternally inactivated mutations of the GNAS1 gene in progressive osseous heteroplasia. N Engl J Med 2002; 346:99–106.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiology, Temple University School of Medicine, 3401 North Broad Street, 19140, Philadelphia, PA, USA

    Akbar Bonakdarpour

  2. Department of Endocrinology and Metabolism, Temple University School of Medicine, Philadelphia, PA, USA

    Colleen Veloski MD (Assistant Professor)

Authors
  1. Akbar Bonakdarpour
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Colleen Veloski MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Akbar Bonakdarpour .

Editor information

Editors and Affiliations

  1. Dept. Diagnostic Imaging, Temple University Hospital, N. Broad Street 3401 , Philadelphia, 19140, U.S.A.

    Akbar Bonakdarpour

  2. Dept. Radiology, Temple University Hospital, Broad Street 3401, Philadelphia, 19140-5189, U.S.A.

    William R. Reinus

  3. Dept. Pathology, Temple University Hospital, N. Broad St. 3401, Philadelphia, 19140, USA

    Jasvir S. Khurana

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Bonakdarpour, A., Veloski, C. (2009). Systematic Approach to Radiology of Endocrine Disorders Affecting the Musculoskeletal System. In: Bonakdarpour, A., Reinus, W., Khurana, J. (eds) Diagnostic Imaging of Musculoskeletal Diseases. Humana Press. https://doi.org/10.1007/978-1-59745-355-4_3

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-355-4_3

  • Published:

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-947-5

  • Online ISBN: 978-1-59745-355-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation